News for Castle Biosciences, Inc. (CSTL)

Castle Biosciences' DecisionDx-Melanoma test and Revolution Medicines' elironrasib cancer drug receive FDA Breakthrough Designations. Read more here.

Castle Biosciences (CSTL) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its DecisionDx-Melanoma

Castle Biosciences' (CSTL) DecisionDx-Melanoma test receives FDA Breakthrough Device designation. The designation accelerates the regulatory pathway for

FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. ( CSTL), a company improving health through innovative tests that guide patient

Shares of Castle Biosciences Inc (CSTL) fell 4.89% in mid-day trading on Jul 18. The stock reached an intraday low of $16.49, before recovering slightly to $1

Castle Biosciences (CSTL) receives multiple prestigious workplace awards in 2025, highlighting strong corporate culture and employee satisfaction. The c

Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards

Castle Biosciences (CSTL) will release its Q2 2025 financial results on August 4, 2025, after market close. The company will host a conference call at 4

FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. ( CSTL), a company improving health through innovative tests that guide patient

Castle Biosciences (CSTL) granted restricted stock units (RSUs) to 66 new employees as part of their 2022 Inducement Plan. The RSU grants cover a total

FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. ( CSTL), a company improving health through innovative tests that guide patient

Shares of Castle Biosciences Inc (CSTL) fell 4.54% in mid-day trading on Jun 17. The stock reached an intraday low of $18.08, before recovering slightly to $1

Castle Biosciences (CSTL) partners with SciBase to develop diagnostic tests for dermatologic diseases. The collaboration targets a U.S. market of 24 mil

Castle Biosciences (CSTL) has signed a collaboration and licensing agreement with SciBase, incorporating SciBase's Electrical Impedance Spectroscopy technology.

**media[656571]**

**media[651586]**

Lake Street will host a virtual meeting featuring Castle Biosciences (CSTL) on June 17. This event offers an excellent opportunity for investors to gain insight

Gold-level Stevie® Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine

Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients FRIENDSWOOD, Texas, May 29, 2